Get the Stockscreener App
3.18
0.32%
0.01
After Hours:
3.18
Cyclerion Therapeutics Inc Stock (CYCN) Forecast
The Cyclerion Therapeutics Inc (CYCN) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $174.31, representing a +5,381% increase from the current price of $3.18. The highest analyst price target is $175.48, and the lowest is $173.14.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CYCN Price Target
Average 143.91
(+4,426% Upside)
Is Cyclerion Therapeutics Inc (CYCN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 53.92 | Neutral |
| STOCH(9,6) | 63.29 | Neutral |
| STOCHRSI(14) | 83.37 | Sell |
| MACD(12,26) | 0.0207 | Buy |
| ADX(14) | 29.50 | Buy |
| William %R | -20.00 | Sell |
| CCI(14) | 48.59 | Neutral |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
3.0164
Buy
|
3.0795
Buy
|
| MA20 |
3.0763
Buy
|
3.0659
Buy
|
| MA50 |
2.949
Buy
|
3.0068
Buy
|
| MA100 |
2.9571
Buy
|
2.9662
Buy
|
| MA200 |
2.8961
Buy
|
2.9628
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, CYCN could be considered a Strong Buy, with 17 technical analysis indicators signaling 12 Buy signals, 2 signaling Sell signals and 3 Neutral signals. This might be a good time to open fresh positions on CYCN, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 53.92 indicates that CYCN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 63.29 indicates that CYCN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 83.37 indicates that CYCN is oversold. This suggests that CYCN price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 29.5 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 48.59 indicates that CYCN is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term CYCN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Cyclerion Therapeutics Inc financial reports and earnings history, Cyclerion Therapeutics Inc (CYCN) stock could reach $435.81 by 2030, $217.10 by 2040 and $721.62 by 2050. See the projected annual prices until 2050 of the Cyclerion Therapeutics Inc stock below:
- Cyclerion Therapeutics Inc (CYCN) is expected to reach an average price of $66.22 in 2035, with a high prediction of $74.34 and a low estimate of $66.28. This indicates an $1,982% rise from the last recorded price of $3.18.
- Cyclerion Therapeutics Inc (CYCN) stock is projected to chart a bullish course in 2040, with an average price target of $210.23, representing an $6,511% surge from its current level. The forecast ranges from a conservative $210.58 to a sky-high $217.10.
- Our analysts predict Cyclerion Therapeutics Inc (CYCN) to jump 13,226% by 2045, soaring from $422.82 to an average price of $423.77, potentially reaching $425.91. While $422.82 is the low estimate, the potential upside is significant.
- Cyclerion Therapeutics Inc (CYCN) stock is expected to climb by 2050, reaching an average of $704.95, a $22,068% jump from its current level. However, a wide range of estimates exists, with high and low targets of $721.62 and $706.55, respectively, highlighting the market's uncertainty.
Cyclerion Therapeutics Inc Stock (CYCN) Year by Year Forecast
Cyclerion Therapeutics Inc Stock (CYCN) Price Forecast for 2025
Cyclerion Therapeutics Inc Stock (CYCN) is expected to reach an average price of $180.07 in 2025, with a high prediction of $252.57 and a low estimate of $107.56. This indicates an +5,562% rise from the last recorded price of $3.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $153.23 | $173.14 | $175.48 | +4,719% |
| August, 2025 | $146.59 | $140.70 | $130.50 | +4,510% |
| September, 2025 | $162.54 | $161.87 | $166.05 | +5,011% |
| October, 2025 | $119.18 | $114.69 | $138.03 | +3,648% |
| November, 2025 | $118.14 | $107.56 | $95.47 | +3,615% |
| December, 2025 | $187.38 | $117.11 | $179.38 | +5,792% |
Cyclerion Therapeutics Inc Stock (CYCN) Price Forecast for 2026
The predicted value for Cyclerion Therapeutics Inc (CYCN) in 2026 is set at an average of $148.16. Estimates vary from a peak of $180.27 to a trough of $116.06, indicating an +4,559% surge from the present price of $3.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $164.54 | $176.14 | $180.27 | +5,074% |
| February, 2026 | $161.39 | $165.09 | $163.31 | +4,975% |
| March, 2026 | $156.44 | $159.24 | $159.27 | +4,820% |
| April, 2026 | $127.89 | $131.60 | $151.33 | +3,922% |
| May, 2026 | $130.84 | $130.84 | $128.66 | +4,015% |
| June, 2026 | $149.40 | $149.13 | $143.62 | +4,598% |
| July, 2026 | $142.04 | $149.84 | $146.08 | +4,367% |
| August, 2026 | $116.99 | $133.99 | $131.79 | +3,579% |
| September, 2026 | $116.44 | $116.06 | $112.36 | +3,562% |
| October, 2026 | $123.19 | $123.81 | $120.79 | +3,774% |
| November, 2026 | $113.55 | $119.15 | $120.97 | +3,471% |
| December, 2026 | $114.79 | $117.39 | $111.43 | +3,510% |
Cyclerion Therapeutics Inc Stock (CYCN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Cyclerion Therapeutics Inc (CYCN) is $114.64, with a high forecast of $128.67 and a low forecast of $100.60. This indicates an +3,505% increase from the last price of $3.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $117.14 | $115.88 | $114.55 | +3,584% |
| February, 2027 | $121.10 | $117.41 | $114.96 | +3,708% |
| March, 2027 | $124.74 | $123.07 | $123.14 | +3,823% |
| April, 2027 | $129.70 | $127.63 | $126.10 | +3,978% |
| May, 2027 | $128.65 | $129.25 | $128.67 | +3,946% |
| June, 2027 | $125.69 | $126.49 | $128.52 | +3,853% |
| July, 2027 | $120.85 | $121.95 | $123.78 | +3,700% |
| August, 2027 | $122.19 | $118.82 | $118.14 | +3,742% |
| September, 2027 | $121.14 | $122.83 | $121.76 | +3,710% |
| October, 2027 | $119.16 | $118.01 | $119.09 | +3,647% |
| November, 2027 | $109.65 | $113.14 | $113.94 | +3,348% |
| December, 2027 | $100.00 | $100.60 | $104.30 | +3,045% |
Cyclerion Therapeutics Inc Stock (CYCN) Price Forecast for 2028
In 2028, Cyclerion Therapeutics Inc (CYCN) is projected to reach an average price of $77.65, with a high projection of $98.57 and a low estimate of $56.73. This indicates an +2,342% rise from the last price of $3.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $96.48 | $98.34 | $98.57 | +2,934% |
| February, 2028 | $92.51 | $93.71 | $93.32 | +2,809% |
| March, 2028 | $93.15 | $93.15 | $96.77 | +2,829% |
| April, 2028 | $83.96 | $89.40 | $91.73 | +2,540% |
| May, 2028 | $83.24 | $80.28 | $80.19 | +2,517% |
| June, 2028 | $75.42 | $77.97 | $79.83 | +2,272% |
| July, 2028 | $70.10 | $72.05 | $74.28 | +2,104% |
| August, 2028 | $67.61 | $68.77 | $68.14 | +2,026% |
| September, 2028 | $68.69 | $68.26 | $66.59 | +2,060% |
| October, 2028 | $65.15 | $66.27 | $67.18 | +1,949% |
| November, 2028 | $60.90 | $60.90 | $63.10 | +1,815% |
| December, 2028 | $56.68 | $56.73 | $59.50 | +1,683% |
Cyclerion Therapeutics Inc Stock (CYCN) Price Forecast for 2029
The 2029 price forecast for Cyclerion Therapeutics Inc Stock (CYCN) is $155.70 on average, with a high prediction of $310.32 and a low estimate of $1.0836. This represents an +4,796% increase from the previous price of $3.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $52.05 | $52.42 | $55.52 | +1,537% |
| February, 2029 | $47.16 | $47.33 | $50.52 | +1,383% |
| March, 2029 | $42.61 | $42.76 | $45.96 | +1,240% |
| April, 2029 | $38.50 | $38.72 | $41.31 | +1,111% |
| May, 2029 | $34.16 | $34.24 | $37.08 | +974.19% |
| June, 2029 | $29.42 | $29.64 | $32.84 | +825.21% |
| July, 2029 | $24.11 | $24.11 | $28.25 | +658.26% |
| August, 2029 | $18.91 | $19.18 | $22.05 | +494.52% |
| September, 2029 | $14.55 | $14.61 | $17.79 | +357.40% |
| October, 2029 | $8.8533 | $9.0233 | $12.94 | +178.41% |
| November, 2029 | $3.9578 | $4.3078 | $7.3419 | +24.46% |
| December, 2029 | $326.72 | $1.0836 | $310.32 | +10,174% |
Cyclerion Therapeutics Inc Stock (CYCN) Price Forecast for 2030
Cyclerion Therapeutics Inc Stock (CYCN) is expected to reach an average price of $449.14 in 2030, with a high forecast of $549.64 and a low forecast of $348.64. This signifies an +14,024% surge from the last price of $3.18.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $452.81 | $365.67 | $435.81 | +14,139% |
| February, 2030 | $390.11 | $405.11 | $403.86 | +12,168% |
| March, 2030 | $454.42 | $404.29 | $433.42 | +14,190% |
| April, 2030 | $429.53 | $453.83 | $447.01 | +13,407% |
| May, 2030 | $364.22 | $348.64 | $401.11 | +11,353% |
| June, 2030 | $381.73 | $407.93 | $415.57 | +11,904% |
| July, 2030 | $550.21 | $550.48 | $549.64 | +17,202% |
| August, 2030 | $536.72 | $542.92 | $547.59 | +16,778% |
| September, 2030 | $504.48 | $524.83 | $522.94 | +15,764% |
| October, 2030 | $481.12 | $484.12 | $493.67 | +15,029% |
| November, 2030 | $500.83 | $479.07 | $481.82 | +15,649% |
| December, 2030 | $493.74 | $494.16 | $490.60 | +15,426% |
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):